$ALGS reports 2022 financial results and optimistic outlook on NASH, COVID-19, and CHB drug candidates.
Mar 9th 2023, 9:06 pm
Analyst Summary: Aligos Therapeutics, a clinical stage biopharmaceutical company, has announced recent business progress and financial results for the fourth quarter and full year 2022. The company's CEO expressed optimism that the drug candidates currently in development are generating positive data and producing results that differentiate them from competitors. The current focus is on NASH, COVID-19, and CHB drug candidates. Aligos expects multiple important data readouts as they continue to drive their programs in 2023. The programs aim to significantly advance shareholder value. Presently, the company has $125.8 million as of December 31, 2021, and cash reserves that will offer sufficient funding for planned operations through the end of 2024. Quotes from the management: “We made great progress advancing our NASH, COVID-19, and CHB drug candidates...Taken together, we expect these programs to have multiple important data readouts as we continue to advance them throughout 2023. These data have the potential to be important drivers of shareholder value and we look forward to sharing them as they emerge." - CEO of Aligos. Forward Looking Statements: The report carries forward-looking statements within the U.S. Private Securities Litigation Reform Act of 1995. The company believes in its cash balance to fund operations through 2024, and its periodic reports to be filed or submitted with the SEC will offer investors comprehensive data on the company status.